A multicenter, randomized, placebo-controlled, double-blind trial to evaluate the effects of vasopressin V2 receptor antagonist on clinical improvement in patients with severe chronic heart failure
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2008
At a glance
- Drugs Satavaptan (Primary)
- Indications Chronic heart failure; Heart failure
- Focus Therapeutic Use
- Acronyms AQUAVIT
- Sponsors Sanofi-Synthelabo
- 16 Jun 2008 Actual patient number 338 added as reported by ClinicalTrials.gov
- 16 Jun 2008 Actual end date changed from Sep 2002 to Feb 2003 as reported by ClinicalTrials.gov.
- 14 Sep 2006 New trial record.